Exposing cancer using the immune-system’s surveillance system – enabling absolute precision targeting
Cells in the human body are constantly surveying for errors and mutations and presenting this survey to the immune system using the Human Leukocyte Antigen (HLA) system.
Myrio leverages this system to assess and unambiguously flag cancer signatures; effectively reaching inside cells for hidden cancer detection, and programming the immune system to precisely kill cancerous cells.
Tailoring immuno-oncology to the patient – engaging with different HLA variants across demographies and making immuno-oncology compatible to all patients.
The peptide-HLA presentation system is a highly diverse system – displaying genetic variants across geographies and demographies around the world.
This can sabotage immuno-oncology therapies that work for one HLA variant to become ineffective or incompatible with another HLA variant.
Myrio’s proprietary platform is unique as the only platform that generates cancer-specific pHLA antibodies that can program the immune-system for different HLA variants. Our antibodies work not just for one HLA patient group, but many patient groups across geographies and demographies.
Add Your Heading Text Here
Exposing cancer using the immune-system’s surveillance system – enabling absolute precision targeting
Cells in the human body are constantly surveying for errors and mutations and presenting this survey to the immune system using the Human Leukocyte Antigen (HLA) system.
Myrio leverages this system to assess and unambiguously flag cancer signatures; effectively reaching inside cells for hidden cancer detection, and programming the immune system to precisely kill cancerous cells.
Tailoring immuno-oncology to the patient – engaging with different HLA variants across demographies and making immuno-oncology compatible to all patients.
The peptide-HLA presentation system is a highly diverse system – displaying genetic variants across geographies and demographies around the world.
This can sabotage immuno-oncology therapies that work for one HLA variant to become ineffective or incompatible with another HLA variant.
Myrio’s proprietary platform is unique as the only platform that generates cancer-specific pHLA antibodies that can program the immune-system for different HLA variants. Our antibodies work not just for one HLA patient group, but many patient groups across geographies and demographies.